Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Pyruvate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.35 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 3/20 | 0.83 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 3/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyruvate SCHEMBL7031058 | 1.00 | CA4 (0.83) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL240885 | 0.96 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL3367247 | 0.92 | — | — | |
| Pyruvate SCHEMBL7941746 | 0.92 | CA4 (0.83) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL20481652 | 0.92 | CA4 (0.92) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL27565126 | 0.92 | — | — | |
| Pyruvate SCHEMBL7935573 | 0.92 | CA4 (0.83) | CA4CA1TSHRTHPOFAHD1 | |
| Pyruvate SCHEMBL148220 | 0.91 | — | — | |
| Pyruvate SCHEMBL18226 | 0.87 | — | — | |
| Pyruvate SCHEMBL7936306 | 0.87 | CA4 (0.91) | CA4CA1TSHRTHPOFAHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170087106-A1 | Method for supporting gut health | PISCHEL IVO (DE) | 2017-03-30 | — | — | US | claimed |
| US-20220040215-A1 | MUSCLE TREATMENT COMPOSITION AND METHOD OF MAKING SAME | Organic Medical Ventures, L.L.C. | 2022-02-10 | — | — | US | disclosed |
| EP-3689343-A1 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF USING ANAPLEROTIC AGENTS | The University of Queensland (AU) | 2020-08-05 | — | — | EP | disclosed |
| US-20190255008-A1 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-08-22 | — | — | US | disclosed |
| US-20180207121-A1 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-07-26 | — | — | US | disclosed |
| US-9937215-B2 | Preparations with rosehip extracts, and method of producing rosehip extracts | FINZELBERG GMBH & CO., KG (DE) | 2018-04-10 | — | — | US | disclosed |
| US-9833430-B2 | Neurodegenerative disorders and methods of treatment and diagnosis thereof | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-12-05 | — | — | US | disclosed |
| US-20170087106-A1 | Method for supporting gut health | PISCHEL IVO (DE) | 2017-03-30 | — | — | US | disclosed |
| EP-3068492-A1 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF | The University of Queensland (AU) | 2016-09-21 | — | — | EP | disclosed |
| US-20160263071-A1 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-09-15 | — | — | US | disclosed |
| US-20040006139-A1 | Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof | DEGUSSA AG (DE) | 2004-01-08 | — | — | US | disclosed |
| WO-2003084351-A1 | USE OF CREATINE PYRUVATE FOR INCREASING STAMINA DURING HIGHLY INTENSIVE INTERMITTENT PHYSICAL EXERTION | BIOGHURT BIOGARDE GMBH & CO. KG (DE) | 2003-10-16 | — | — | WO | disclosed |
| EP-1343490-A1 | CHOLINE PYRUVATE, METHOD FOR THE PRODUCTION THEREOF, FORMULATIONS CONTAINING CHOLINE PYRUVATE AND THE USE THEREOF | Degussa AG (DE) | 2003-09-17 | — | — | EP | disclosed |
| EP-0993433-B1 | METHOD FOR PRODUCING CALCIUM PYRUVATES | DEGUSSA (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2002051398-A1 | CHOLINE PYRUVATE, METHOD FOR THE PRODUCTION THEREOF, FORMULATIONS CONTAINING CHOLINE PYRUVATE AND THE USE THEREOF | DEGUSSA AG (DE) | 2002-07-04 | — | — | WO | disclosed |
| US-6342631-B1 | METHOD OF PRODUCING CALCIUM PYRUVATES IS DESCRIBED, IN WHICH CALCIUM SALTS OF ORGANIC ACIDS OR ACIDIC ORGANIC KETO OR HYDROXY COMPOUNDS ARE REACTED WITH PYRUVIC ACID TO FORM COMPOUND WITH LONG SHELF LIFE | SKW TROSTBERG AKTIENGESELLSCHAFT (DE) | 2002-01-29 | — | — | US | disclosed |
| EP-0993433-A1 | METHOD FOR PRODUCING CALCIUM PYRUVATES | SKW Trostberg Aktiengesellschaft (DE) | 2000-04-19 | — | — | EP | disclosed |
| US-5962734-A | Method of producing calcium pyruvates | SKW TROSTBERG AKTIENGESELLSCHAFT (DE) | 1999-10-05 | — | — | US | disclosed |
| WO-1999002479-A1 | METHOD FOR PRODUCING CALCIUM PYRUVATES | SKW TROSTBERG AKTIENGESELLSCHAFT (DE) | 1999-01-21 | — | — | WO | disclosed |
| US-5723661-A | SALT FORMATION USING CALCIUM COMPOUND WITH PYRUVIC ACID | DSM CHEMIE LINZ GMBH (AT) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255008-A1 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF | NLN, SLC25A20, SMN1; SMN2 | MEN1 2562/4885THRB 3902/4885CA4 2015/4885 |
| US-20180207121-A1 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF | NLN, SLC25A20, SMN1; SMN2 | MEN1 2562/4885THRB 3902/4885CA4 2015/4885 |
| US-20160263071-A1 | NEURODEGENERATIVE DISORDERS AND METHODS OF TREATMENT AND DIAGNOSIS THEREOF | NLN, SLC25A20, SMN1; SMN2 | MEN1 2562/4885THRB 3902/4885CA4 2015/4885 |
| US-20040006139-A1 | Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof | PDK1, PC, PDK4 | MEN1 1006/4885THRB 1081/4885CA4 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.